| 翻訳と辞書 |
RP5063
RP5063, also known as RP5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism.〔(【引用サイトリンク】 publisher = Reviva Pharmaceuticals )〕〔(【引用サイトリンク】 publisher = Reviva Pharmaceuticals )〕 As of May 2015, it is in phase III clinical trials for schizophrenia.〔〔
==Pharmacodynamics==
RP5063 is frequently described as a so-called "dopamine-serotonin system stabilizer" due to its unique actions on the dopamine and serotonin neurotransmitter systems compared to other antipsychotics.〔 Specifically, it acts as a partial agonist of the D2, D3, and D4 receptors and of the 5-HT1A and 5-HT2A receptors, and as an antagonist of the 5-HT6 and 5-HT7 receptors.〔〔〔 RP5063 has high affinity for the D2S, D2L, D3, D4.4, 5-HT1A, 5-HT2A, 5-HT7, and H1 receptors, and moderate affinity for the D1, D5, 5-HT3, 5-HT6 receptors, the SERT, and the α1B-adrenergic receptor.〔 It lacks significant affinity for the 5-HT1B, 5-HT2C, α2-adrenergic, and mACh receptors, as well as for the NET and DAT.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「RP5063」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|